FindTrial
Sign In

An open study comparing the effects of moxaverine on ocular blood flow in patients with age- related macular degeneration, primary open angle glaucoma and healthy control subjects - Moxaverine – Patients OPHT-011007

An open study comparing the effects of moxaverine on ocular blood flow in patients with age- related macular degeneration, primary open angle glaucoma and healthy control subjects - Moxaverine – Patients OPHT-011007

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-005607-18-AT
Enrollment
Unknown
Registered
2008-03-04
Start date
2009-04-02
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma age-related macular degeneration MedDRA version: 9.1 Level: LLT Classification code 10036719 Term: Primary open angle glaucoma MedDRA version: 9.1 Level: LLT Classification code 10064930 Term: Age-related macular degeneration

Interventions

Product Name: Moxaverine Pharmaceutical Form: Intravenous infusion INN or Proposed INN: MOXAVERINE CAS Number: 10539192 Concentration unit: mg milligram(s) Concentration type: equal Concentration numb

Sponsors

Ursapharm Arzneimittel GmbH & Co KG
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: men and women aged over 50 years patients with age related macular degeneration: stage AREDS II, III or IV, visual acuity > 20/60 patients with primary open angle glaucoma: treated intraocular pressure =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Diabetes uncontrolled IOP other ocular vascular disease intraocular surgery within the last 3 months

Design outcomes

Primary

MeasureTime frame
Main Objective: To compare the effect of moxaverine on ocular blood flow in patients with age related macular degeneration, primary open angle glaucoma and healthy control subjects;Secondary Objective: ;Primary end point(s): Choroidal and optic nerve head blood flow (Laser Doppler Flowmetry)—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026